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BACKGROUND: Orbital exenteration is a destructive procedure performed by removing all or part of 
the orbital contents along with entire eyeball. It is a procedure reserved for life threatening malignancies 
and some nonmalignant disorders which are not controlled by conservative management. 
METHODS: This is a retrospective study done on patients who underwent orbital exenteration at 
Tilganga Institute of Ophthalmology from1 January 2006- 30 in December 2014.  
RESULTS: The mean age of patients was 30 years (range 1-78), with male preponderance of 15(55.6%. 
Overall presenting duration of eye morbidity was 18 months (2 months-8.5 years). The most common 
presenting complaint was protrusion of eyeball1, 4(50%), primary site of tumor being intraocular in 10 
patients (35.7%,) and total orbital exenteration was the most commonly performed type of surgery in 
16(57.1%) out of 27 patients. The most common etiology responsible for orbital exenteration, in pediatric 
age group of 9/27 patients (64.2%), was retinoblastoma whereas conjunctival squamous cell carcinoma 
(SCC)accounts for 5 patients (38.4%) in adults. Overall, the most common cause of orbital exenteration 
was retinoblastoma 9(32.1%). 
CONCLUSION: The most common etiologies requiring orbital exenteration were retinoblastoma (in 
children and overall) and conjunctival squamous cell carcinoma (in adults), both diseases that could be 
addressed with less invasive treatment modality if detected earlier in the disease process. Designing 
strategy is important for early detection and treatment of these conditions, which would decrease disease 
morbidity and prognosis, potentially sparing sight and life.  
KEYWORDS: Orbital exenteration, histopathology patterns, retinoblastoma, squamous cell carcinoma, 
proptosis, Nepal 
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INTRODUCTION  
 
Orbital exenteration, first described by George 
Bartisch in 1583(1), is a destructive procedure 
performed by removing all or part of the orbital 
contents along with the entire eyeball. 
Exenteration is performed when tumors of ocular 
surface, eyelid, lacrimal gland or intraocular tumor 
invade orbital tissues, in order to control the 
progression of the tumor from the orbit to the 
surrounding tissues and to distant organs. In 
addition, benign lesions causing massive 
proptosis, uncontrolled recurrent bleeding and 
severe uncontrolled infections may warrant 
exenteration (2-6).  
In literature review, the common indications for 
exenteration were found to be eyelid malignancy 
and orbital tumor (2,3,4,7). According to 
geographical locations, reports on common 
etiologies requiring exenteration variy Rahman et 
al (3), Wong et al (8) from the United Kingdom 
and Duman et al (4) from Turkey reported basal 
cell carcinoma as theleading pathology requiring 
exenterationwhereas Nemet et al from Australia 
reported Squamous cell carcinomaas as the most 
common cause (5). 
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To our knowledge, there is no data on the clinico-
pathological pattern of exenteration in Nepal. The 
aim of the current study is to investigate the 
magnitude, presenting symptoms, indications and 
histopathology findings of patients who underwent 
orbital exenteration at a tertiary referral eye 
hospital in Kathmandu, Nepal. 
 
METHODS AND SUBJECTS  
 
This is a retrospective study conducted on patients 
who underwent orbital exenteration from 1 
January 2006 to 30 December 2014, at Tilganga 
Institute of Ophthalmology, Nepal. The study was 
approved by the Institutional Review Board of 
Tilganga Institute of Ophthalmology. 
All surgeries were performed under general 
anesthesia, and orbital exenteration was classified 
into three types(2).  
1. Subtotal exenteration which was done by 
removing the globe for tumors involving the 
globe and conjunctiva and orbital contents but 
sparing the orbital periosteum  and all or part 
of the eye lid. 
2. Total exenteration which was done by 
removing all orbital contents along with the 
periosteum and eye lid; and  
3. Eextended exenteration which was done by 
removing the orbital contents, periosteum, eye 
lid, and part of the orbital bone and paranasal 
sinus tissue  
Each patient’s medical records were reviewed 
to determine the presenting signs and symptoms, 
duration of symptoms prior to presentation, visual 
acuity at presentation, primary location of 
pathological lesions, indications for exenteration, 
clinical diagnosis, exenteration type and finally 
histopathology diagnosis. Surgical approach and 
adjunctive postoperative management were also 
reviewed. 
A total of 31 eyes of 30 patients who 
underwent exenteration were identified and 
reviewed. Three of the 31eyes were excluded 
because of incomplete data documentation. 
Twenty-eight eyes of 27 patients were finally 
allocated for analysis. Statistical calculation was 





The mean age of the study subjects was 30 years 
(ranging: 1-78 years) with 14/27 (52%) patients 
being children of less than 15 years old. The 
majority of the patients were male, 15/27 (55.6%). 
The most common presenting complaints were 
proptosis, 14/27 (50.0%), followed by ocular 
surface growth, 5/27(17.9%), and decreased 
vision, 4/27(14%). The mean duration of 
symptoms prior to presentation was 18 months 
(range: 2 months –8.5 years), and majority of the 
patients presented within ≤ one month15 (53.6%). 
A right eye preponderance, 17/27(63.0%), was 
also noted, and one patient had both eyes affected 
by orbital retinoblastoma (Table 1). 
The most common primary anatomical site of 
pathology responsible for exenteration was 
intraocular, 10(35.7%), followed by orbit, 
8(28.6%). The most common surgical approach 





















Table1: Socio-demographic and clinical characteristics of orbital exenteration study patients. 
 
We found that a large proportion of study patients 
had never consulted an eye health care facility, 
9/27 (33%) patients, and of the remaining 18 
patients who visited eye care facility, 12/27 (44%) 
had received some form of treatment prior to 
exenteration. Among the 12 patients who had prior 
intervention, 10 of the 12 patients received 
chemotherapy (3 patients for retinoblastoma and 6 
topical chemotherapy). Among the 10 patients 
who received chemotherapy, one had received 
additional endolaser for retinoblastoma and 
another one had undergone enucleation for 
































receive chemotherapy before exenteration, one 
underwent incisional biopsy and the other had 
undergone enucleation prior to exenteration. 
         Histopathology demonstrated malignant 
tumors in the majority of our study patients, 
except in one patient where it showed a benign 
cystic lymphangioma. Overall, the most frequent 
malignant tumors identified were retinoblastoma, 
9/27(32.1%), conjunctival squamous cell 
carcinoma, 5/27 (17.9%) and basal cell carcinoma 
of eyelid 3/27(10.7%) (Table 3).  
In 17/28(60.7%) of the cases, the surgical margin 
was infiltrated by tumor for which the patients 
were referred to an oncologist for further 






Variables          Number of Participants (n=27) Percentage (%) 
Age in years 
  
≤ 15 14 51.9 
 > 15 13 48.1 
Sex Number of Participants (n=27) 
 
Male 15 55.5 
Female 12 44.5 
Presenting chief complaint Number of Eyes (n=28) 
 
Protrusion of eyeball 14 50 
Ocular Surface growth 5 17.9 
Decreased vision 4 14.3 
Eyelid mass 3 10.7 
Leucocoria 2 7.1 
Duration of presenting complaint Number of Eyes (n=28) 
 
≤ 1month 15 53.6 
1 month - 1 year 8 28.6 
> 1 year 5 17.8 
Laterality of Surgery Number of Participants (n=27) 
 
Unilateral 26 96.3 
Bilateral 1 3.7 
Affected eye Number of Participants (n=27) 
 
Right 17 63.0 
Left 9 33.3 
Both 1 3.7 


















Table 3: Histopathology reports and surgical margin involvement pattern among patients undergone 
exenteration in the study (n=28). 
 
Variables  No. % 
Histopathology diagnosis 
Retinoblastoma 9 32.1 
Conjunctiva squamous cell carcinoma 5 17.9 
Non-Hodgkin’s lymphoma 2 7.1 
Malignant eye lid melanoma 2 7.1 
Rhabdomyosarcoma  2 7.1 
Basal cell carcinoma 1 3.6 
olfactory neuroblastoma  1 3.6 
Chroidal melanoma 1 3.6 
Angiosarcoma 1 3.6 
Malignant fibrous histiocytoma 1 3.6 
Benign cystic lymphangioma 1 3.6 
Surgical margin   
Involved with the tumor 23 82.1 
Not involved with the tumor 3 10.7 
Unknown  2 7.1 
 
In this study, we found that orbital retinoblastoma 
was the most common indication of exenteration 
in children (≤ 15 years old) while conjunctival 
squamous cell carcinoma was the most common 
indication in adults (> 15 years old), accounting 
for 9/14(64.2%) and 5/13(38.5%) cases, 




Exenteration is a procedure reserved for life 
threatening malignancies. It is done for some 
nonmalignant disorders that are not controlled by 
conservative management. 
The most common presentation was found to be 
proptosis in 14/28 cases (50%) which was 
consistent with results of Kauret et al previous 
report (9). The most common indication for 
exenteration in our study was retinoblastoma 
(32.1%), and this was discordant with other 
literature findings (3 4, 8, 9) which reported that 
eyelid tumor was the most common etiology 
responsible for exenteration. This could be due to 
the distribution of patient age group in our study, 
consisting equal number of children and adults 
with high occurrence of retinoblastoma 
responsible for exenteration in childhood. We 
observed orbital tumor as the second most 
common primary site of tumor responsible for 
exenteration, which is similar with the findings of 
other studies (3, 4,8). 
Primary site of tumor 
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Histopathology findings suggest retinoblastoma,  
9(32.1%) as the leading cause for exenteration, 
which is comparable to Verma et al’s report from 
Papua New Guinea, where retinoblastoma 
accounted for 40.3% of the exenterationcases (10). 
This finding was not consistent with the results 
of other studies (3-5). This might be due to 
differences in study area, study population, disease 
epidemiology and level of awareness about the 
disease. Retinoblastoma is a common eye and 
adnexal tumor that often presents late in Nepal 11-
13). Late presentation may be the result of lack of 
awareness about the disease, which ultimately 
necessitates exenteration to save the patient or as 
palliative therapy. 
 In addition,we found conjunctival squamous 
cell carcinoma, 5(17.9%), to be the second most 
common histopathological diagnosis requiring 
exenteration. This finding was similar with those 
noted in studies by Verma et al(10), Nemet et 











This study revealed total exenteration of 
16(57.1%) as the most common surgical 
procedure followed by sub-total of 11(39.3%) and  
extended exenteration of 1(3.6%). This finding 
was consistent with those noted in studies by 
Rahman et al. and Nemet et al. (3,5). The need for 
frequent total exenteration may be due to late 
presentation and the need for extensive tumor 
removal in our case series. 
Although studies have shown that tumor free 
margins on histology can prevent recurrences of 
tumors but have little effect on long-term survival 
(16, 17), we found a large proportion of cases, 
17(60.7%), with positive surgical margins. This is 
higher than the ones reported by Rahman et al. 
29(42.0%) (3), Ben Simon 11(32%) (18) and 
Rahman et al 30 (46.9%) (16). This difference 
could be due to late presentation of the patient 
resulting in patients with advanced disease 
condition excision continuing to have positive 
histologic margins. On the other hand, the 
difference in surgical protocol of each center 
could contribute to the variation. 
The limitation of this study is its retrospective 
design. However,the need for exenteration in 
diseases where a prospective study is not feasible. 
                                     Age<15 years(mean  4.1+2.89) 






Retinoblastoma                                          9(64.3) 3(21.4) 6(42.9) 
Non-Hodgkin’s Lymphoma 2(14.3) 2(14.3) 0(0.0) 
Rhabdomyosarcoma 2(14.3) 2(14.3) 0(0.0) 
Benign Cystic Lymphangioma 
Total 
     1(7.1) 1(7.1) 0(0.0) 
14(100.0) 8(57.1) 6(42.9) 
                                     Age >15 years (mean  61.2+10.7) 






Conjunctiva squamous cell carcinoma 
Basal Cell Carcinoma 
5(38.5)  2(15.4) 3(23.1) 




2(15.4))    1(7.7) 1(7.7) 
1(7.7)    1(7.7) 0(0.0) 
1(7.7)    1(7.7) 0(0.0) 
Angiosarcoma 1(7.7)    1(7.7) 0(0.0) 
Malignant Fibrous Histiocytoma 1(7.7) 0(0.0) 1(7.1) 
Total 13(100.0) 7(53.8) 6(46.2) 





In conclusion, retinoblastoma in children and 
conjunctival squamous cell carcinoma in adults 
were the leading causes of orbital exenteration in 
our study. In both cases, early detection and 
treatment can often salvage vision and the globe, 
while also preventing more severe local 
infiltration and metastasis. Improved patient 
awareness about ocular and orbital neoplasms 
may, in turn, lead to earlier presentation and 
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